EXPERIENCE IN THE USE OF DOUBLE BLOCKADE OF THE HER2 RECEPTOR IN NEOADJUVANT MODE IN THE TREATMENT OF BREAST CANCER IN THE DEPARTMENT OF BREAST TUMORS OF THE CHOKTSOYAM STATE MEDICAL INSTITUTION

Korostelev Alexander Mikhailovich, Tereshin Oleg Stanislavovich, Bulynsky Denis Nikolaevich, Samylov Vitaly Vadimovich

The authors investigated their own experience of using double blockade of the HER2 receptor with the use of Trastuzumab and Pertuzumab in combination with chemotherapy for neoadjuvate therapy of breast cancer in routine clinical practice. The frequency of pathomorphological responses on the RCB scale after radical surgery was determined. In the studied group (N=53), the frequency of complete pathomorphological responses (pCR) was 52.8%. The highest frequency of pCR was registered in the subgroup of the non-luminal HER2 positive subtype of breast cancer. Adverse events in the vast majority of cases were represented by anemia and neutropenia of I-II degrees. Neoadjuvant therapy with the use of double HER2 blockade allows increasing the number of organ-preserving operations in patients with localized forms of breast cancer.

Keywords:breast cancer, neoadjuvant therapy, HER2 receptor, targeted therapy, Trastuzumab, Pertuzumab, residual tumor, mastectomy, organ-preserving treatment